CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 183 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2023. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,210 | +282.2% | 116,322 | +299.5% | 0.04% | +260.0% |
| Q1 2024 | $1,363 | -70.0% | 29,119 | -77.2% | 0.01% | -66.7% |
| Q4 2023 | $4,543 | +427.6% | 127,682 | +341.2% | 0.03% | +275.0% |
| Q3 2023 | $861 | -75.1% | 28,939 | -84.9% | 0.01% | -71.4% |
| Q2 2023 | $3,459 | +46.4% | 191,974 | +30.5% | 0.03% | +40.0% |
| Q1 2023 | $2,363 | – | 147,116 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 479,681 | $21,484,912 | 8.12% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $6,315,390 | 7.68% |
| STEMPOINT CAPITAL LP | 551,095 | $24,683,545 | 7.25% |
| EcoR1 Capital, LLC | 4,155,375 | $186,119,246 | 5.69% |
| ACUTA CAPITAL PARTNERS, LLC | 135,141 | $6,052,965 | 5.10% |
| First Light Asset Management, LLC | 1,200,508 | $53,770,753 | 4.71% |
| Ikarian Capital, LLC | 588,818 | $26,373,158 | 4.59% |
| Paradigm Biocapital Advisors LP | 2,513,302 | $112,570,797 | 4.31% |
| MPM BioImpact LLC | 557,184 | $24,956,271 | 3.88% |
| Cormorant Asset Management, LP | 1,350,000 | $60,466,500 | 3.49% |